<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00674752</url>
  </required_header>
  <id_info>
    <org_study_id>A9451157</org_study_id>
    <nct_id>NCT00674752</nct_id>
  </id_info>
  <brief_title>A Polysomnographic Study Of Single-Dose Gabapentin In Transient Insomnia</brief_title>
  <official_title>A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter, Polysomnographic Study Of Gabapentin 250 mg And 500 mg In Transient Insomnia Induced By A Sleep Phase Advance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of gabapentin on polysomnographic
      assessments in transient insomnia induced by a sleep phase advance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wake after sleep onset as measured by polysomnography (PSG)</measure>
    <time_frame>Hour +8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSG Latency to Persistent Sleep</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG Wake Time During Sleep</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG WASO</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG Sleep Onset Latency</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karolinska Sleep Diary-Sleep (KSD) Quality Index</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KSD individual scores</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG NA</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Hour +13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG Total wake time plus Stage 1 sleep</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG TST</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG Sleep Efficiency</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG Percent of Stages 1, 2, 3, 4 and REM sleep</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG Percent slow wave sleep (Stages 3&amp;4 combined)</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subjective Sleep Latency</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subjective Number of Awakenings (NA)</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subjective Wake After Sleep Onset (WASO)</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subjective Total Sleep Time (TST)</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subjective Assessment of Sleep Refreshment</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subjective Assessment of Sleep Quality</measure>
    <time_frame>Hour +8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">377</enrollment>
  <condition>Transient Insomnia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Gabapentin 250 mg oral capsule 30 minutes prior to bedtime</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Gabapentin 500 mg oral capsule 30 minutes prior to bedtime</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo oral capsule 30 minutes prior to bedtime</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged &gt;/= 18 years who reported occasional sleeplessness in the month prior to
             screening

          -  Females of child-bearing potential using medically-acceptable method of birth control
             &gt;/= 1 month prior to screening

        Exclusion Criteria:

          -  Current or recent history (within 2 years) of sleep disorder (excessive snoring,
             obstructive sleep apnea, chronic painful condition)

          -  Currently taking or expected to take any of the following during the trial:
             amphetamines, benzodiazepines, cocaine, marijuana, methaqualone, methadone, opiates,
             propoxyphene, barbituates, and phencyclidine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9451157&amp;StudyName=A%20Polysomnographic%20Study%20Of%20Single-Dose%20Gabapentin%20In%20Transient%20Insomnia%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2008</study_first_submitted>
  <study_first_submitted_qc>May 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2008</study_first_posted>
  <last_update_submitted>April 22, 2011</last_update_submitted>
  <last_update_submitted_qc>April 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

